Ones To Watch News
Refine Search
Biotechnology
Privately-held US biotech Teon Therapeutics has announced the appointment of Serge Messerlian as chief executive and member of the board of directors. 9 March 2022
Biosimilars
Privately-held Icelandic biosimilars developer Alvotech Holdings says it has executed a US settlement agreement with AbbVie that grants Alvotech non-exclusive rights to market AVT02 (100mg/mL), its high-concentration, citrate-free biosimilar candidate for Humira (adalimumab) in the USA 9 March 2022
Biotechnology
Confirming that BioNTech is not just a one trick pony - having been behind the discovery of the most successful COIVD-19 vaccines, the German biotech today announced the expansion of its strategic collaboration with Regeneron to advance the company’s FixVac candidate BNT116 in combination with Libtayo (cemiplimab), a PD-1 inhibitor, in advanced non-small cell lung cancer (NSCLC). 8 March 2022
Biotechnology
Private UK-based cell and gene therapy company Ixaka, previously known as Rexgenero, has announced that Advanced Therapy Medicinal Product (ATMP) classification has been granted by the European Medicines Agency (EMA) for its Chemically Encapsulated Lentiviral vector for Targeted In Vivo CAR T-cell therapy (CELTIC-19) targeted nanoparticle (TNP) product. 8 March 2022
Pharmaceutical
German CNS specialist Neuraxpharm Group today announced the expansion of its business in Southeast Europe through the acquisition of Greece-headquartered Brain Therapeutics, a CNS-focused marketing and distribution company with longstanding expertise in commercialization of CNS products in Greece, Cyprus and the Balkan countries. 8 March 2022
Pharmaceutical
Following the filing of a Citizen Petition last Friday by French drug major Sanofi calling on the US Food and Drug Administration to review the labels for influenza vaccines from Seqirus, a subsidiary of Australia’s CSL Limited, Seqirus has issued its own view. 8 March 2022
Biotechnology
Microbiotica has raised $67 million in a series B funding round, the largest microbiome-related financing in Europe to date. 7 March 2022
Pharmaceutical
Spanish drugmaker PharmaMar’s shares closed down 7.5% at 54.90 euros on Friday, despite announcing the receipt of payment of $25 million (22 million euros) from its US partner, Jazz Pharmaceuticals (Nasdaq: JAZZ), after reaching the first commercial milestone, set out in its license agreement in relation to 2021 sales. 7 March 2022
Pharmaceutical
Following Discussion with the US Food and Drug Administration, Karyopharm Therapeutics plans to initiate a new placebo-controlled randomized study of selinexor in the advanced or recurrent endometrial cancer p53 wild-type population. 3 March 2022
Biotechnology
Shares of Synairgen, the UK respiratory company developing SNG001, leapt more than 36% to 25.16 pence by late morning trading, after it announced an update on SNG001 in the ACTIV-2 Phase III trial for COVID-19 and on SNG001 activity against Delta and Omicron variants. 3 March 2022
Biotechnology
Privately-held Swiss ophthalmology company Oculis and private Spanish translational neuroscience R&D company, Accure Therapeutics, have announced a licensing agreement. 2 March 2022
Biotechnology
Rondo Therapeutics, a new immune-oncology-focused biotech based in San Francisco, USA, today emerged from stealth mode with its announcement of an oversubscribed $67 million Series A round of funding. 2 March 2022
Biotechnology
UK and USA-based clinical-stage biopharmaceutical company F-star Therapeutics has appointed James Sandy as chief development officer (CDO), effective March 1. 2 March 2022
Biotechnology
Legend Biotech, a clinical stage CAR-T immuno-oncology biotech spun out of Hong Kong-listed GenScript Biotech, says that the US Food and Drug Administration has approved its first product, Carvykti (ciltacabtagene autoleucel; cilta-cel). 1 March 2022
Biotechnology
Shares of Ireland-headquartered rare diseased biotech Amryt Pharma fell as much as 31% yesterday, after it announced the receipt of a Complete Response Letter (CRL) from the US Food and Drug Administration regarding its New Drug Application (NDA) for Oleogel-S10. 1 March 2022
Biotechnology
Shares of Belgium biotech Celyad Oncology closed down 13.8% at 2.46 euros yesterday, after it announced it has taken the decision to voluntarily pause the CYAD-101-002 (KEYNOTE-B79) Phase Ib trial (NCT04991948). 1 March 2022
Biotechnology
US biotech Affinivax yesterday announced it has reacquired the exclusive worldwide rights to ASP3772, a novel vaccine candidate targeting Streptococcus pneumoniae, from Japanese pharma major Astellas Pharma. 1 March 2022
Pharmaceutical
Denmark-based vaccines developer Bavarian Nordic today announced additional positive results from a Phase II clinical trial of its non-adjuvanted COVID-19 vaccine candidate, ABNCoV2, which is being developed as a universal booster vaccine. 28 February 2022
Pharmaceutical
US neuroscience drug developer Biohaven Pharmaceutical on Friday announced that it has entered into a definitive agreement to acquire Channel Biosciences, a subsidiary of Knopp Biosciences. 26 February 2022
Biotechnology
Canadian biopharma company Medicago and UK pharma major GlaxoSmithKline have announced that Health Canada has granted approval for Covifenz, COVID-19 vaccine, (plant-based virus-like particles [VLP], recombinant, adjuvanted). 25 February 2022
Biotechnology
Epitopea, a UK and Canada-based cancer immunotherapeutics company, has partnered with nucleic acid delivery specialist Genevant Sciences to develop new RNA-based therapies targeting proprietary tumor antigens. 20 December 2024
Pharmaceutical
US biotech Assembly Biosciences has announced an equity investment of $20.1 million by Gilead Sciences to purchase additional common stock in the company and an amendment to their collaboration to advance the research and development of novel antiviral therapies with $10 million in accelerated funding. 20 December 2024
Pharmaceutical
Privately-held Xcovery Holdings, an oncology-focused pharma company, has announced that the US Food and Drug Administration (FDA) has approved Ensacove (ensartinib) for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC). 19 December 2024
Biotechnology
Privately-held biotech Ottimo Pharma today announces the completion of a Series A financing round of over $140 million. 19 December 2024
Biotechnology
Safi Biotherapeutics, a specialist in stem-cell derived red blood cell products, has received Rare Pediatric Disease designation and Orphan Drug designation from the US regulator. 19 December 2024
Biotechnology
BioAge Labs today announced a multi-year research collaboration with Swiss pharma giant Novartis, with the news pushing the US biotech’s shares up 6.1% to $4.35 by early afternoon. 18 December 2024
Pharmaceutical
Marking its second deal this month alone, Novo Nordisk has entered into a multi-year collaboration with Massachusetts, USA-based Photys Therapeutics to develop novel proximity-based therapeutics for a cardiometabolic disease target. 18 December 2024
Biotechnology
Cara Therapeutics and Tvardi Therapeutics have announced a definitive agreement to merge, creating a new entity under the Tvardi name. 18 December 2024
Pharmaceutical
SiteOne Therapeutics has announced the completion of a $100 million series C financing, led by Novo Holdings, with participation from OrbiMed, Wellington Management, Mission BioCapital, and others. 18 December 2024
Biotechnology
Flagship Pioneering-founded genome engineering biotech Tessera Therapeutics today announced an investment of up to $50 million from the Bill & Melinda Gates Foundation to develop curative, globally accessible in vivo genetic therapies for sickle cell disease. 18 December 2024
Biotechnology
San Francisco-based Indapta Therapeutics, a privately held start-up developing next-generation cell therapies, has raised $22.5 million in a new financing round. The firm raised over $50 million in series A funding in 2022. 18 December 2024
Biotechnology
French CNS specialist Theranexus saw its shares leap more than 34% to 0.65 euros as it revealed a license and supply agreement with Exeltis to commercialize TX01, its novel formulation of a compound already approved in the indication for the treatment of rare neurological diseases. 18 December 2024
Biotechnology
Shares in US biopharma Viridian Therapeutics shot up by 21% on Monday. 17 December 2024
Biotechnology
US antivirals giant Gilead Sciences today revealed it has entered into a strategic collaboration to discover and develop novel, small molecule therapies across multiple targets with Californian biotech Terray Therapeutics. 17 December 2024
Pharmaceutical
Swedish biotech company Inify Laboratories has raised approximately 135 million kroner ($12.3 million) through a private placement, supporting a planned expansion into the UK. 16 December 2024
Biotechnology
Dewpoint Therapeutics and ConcertAI have announced the first phase of their translational oncology partnership, aligned around the former company's latest drug candidate, DPTX3186. 16 December 2024
Biotechnology
Bicycle Therapeutics, a UK-headquartered pharma company developing a new class of therapeutics based on its proprietary bicyclic peptide technology, closed a third lower on Friday. 16 December 2024
Biotechnology
In a filing with the US financial regulator, German mRNA specialist BioNTech has noted the lifting of a partial clinical hold on its PRESERVE-003 trial. 16 December 2024
Biotechnology
VectorY Therapeutics, a Netherlands-based biotech focused on neurodegenerative diseases, has appointed Jim Scibetta as chief executive officer. 16 December 2024
Biotechnology
Sino-American biotech BeiGene has announced it has entered into a global licensing agreement with China’s CSPC Zhongqi Pharmaceutical Technology for SYH2039, a novel methionine adenosyltransferase 2A (MAT2A)-inhibitor being explored for solid tumors. 13 December 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze